Denosumab Agents (Prolia, Xgeva, and Biosimilars) — Clinical Coverage Criteria
Customize your policy alerts
Sign up for Anthem Policy CC-0027 alerts
Get alerted when Policy CC-0027 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage criteria, step therapy, quantity limits, and coding for denosumab products (Prolia, Xgeva, and listed biosimilars) for osteoporosis and metabolic bone disease; applies to Anthem medical benefit reviews and prior authorization determinations.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.